Surrey Heartlands

Joint Formulary & PAD

Ustekinumab - Psoriatic arthritis

You are here : Home > Formulary Search > Ustekinumab - Psoriatic arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Psoriatic Arthritis High cost immunomodulator drug pathway Apr-24.pdf
Policy Statement
Ustekinumab for PsA - Policy statement APC 167-2015 Sep2015.pdf
NICE Technology Appraisal
NICE TA340 - Ustekinumab for treating active psoriatic arthritis
Miscellaneous
Ustekinumab in Psoriatic Arthritis - Briefing Paper - September 2015
Information
PCN post meeting clarification - NICE TA - December 2016

PAD Profile

ChemicalSubstance :
Ustekinumab
Indication :
Psoriatic arthritis
Group Name :
Keywords :
PsA, Biologic, cytokine modulator
Brand Names Include :
Stelara, Uzpruvo, Pyzchiva, Wezenla, Steqeyma, Imuldosa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Ustekinumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriatic arthritis.

Committee Recommendations (3)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated  Psoriatic arthritis high cost immunomodulator treatment pathway.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. 

02 Sep 15 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends Ustekinumab as a treatment option for treating active Psoriatic Arthritis in adults in line with NICE TA340.